Natanael Zarco

Jun 9, 2024 | biorxiv.org | Steven Rosenfeld |Natanael Zarco |Athanassios Dovas |Virginea Farias

AbstractWhile mitotic spindle inhibitors specifically kill proliferating tumor cells without the toxicities of microtubule poisons, resistance has limited their clinical utility. Treating glioblastomas with the spindle inhibitors ispinesib, alisertib, or volasertib creates a subpopulation of therapy induced senescent cells that resist these drugs by relying upon the anti-apoptotic and metabolic effects of activated STAT3.